Cookie Settings

We use cookies to optimize our website. These include cookies that are necessary for the operation of the site, as well as those that are only used for anonymous statistic. You can decide for yourself which categories you want to allow. Further information can be found in our data privacy protection .


These cookies are necessary to run the core functionalities of this website and cannot be disabled.

Name Webedition CMS
Purpose This cookie is required by the CMS (Content Management System) Webedition for the system to function correctly. Typically, this cookie is deleted when the browser is closed.
Name econda
Purpose Session cookie emos_jcsid for the web analysis software econda. This runs in the “anonymized measurement” mode. There is no personal reference. As soon as the user leaves the site, tracking is ended and all data in the browser are automatically deleted.

These cookies help us understand how visitors interact with our website by collecting and analyzing information anonymously. Depending on the tool, one or more cookies are set by the provider.

Name econda
Purpose Statistics
External media

Content from external media platforms is blocked by default. If cookies from external media are accepted, access to this content no longer requires manual consent.

Name YouTube
Purpose Show YouTube content
Name Twitter
Purpose activate Twitter Feeds a European initiative to better understand cancer

Kick-off meeting for the Coordination and Support Action

No. 53c | 26/09/2022

The Coordination and Support Action "" had its official kick-off on September 8-9 2022 with a public event hosted by Inserm at les Cordeliers, Paris, France.

© CSA : Pave the way for initiative
An initiative to better UNderstand CANcer ( is part of the implementation roadmap of two programs of the European Union (EU), Europe's Beating Cancer Plan and the Horizon Europe Mission on Cancer. The role of CSA is to prepare a blueprint for within the next 15 months.
The German Cancer Research Center (DKFZ) attaches great importance to European networking in the fight against cancer and is intensively involved in this important European project as a core partner of
"The intensive collaboration from scientists of across the EU within the EU Cancer Mission will provide an important boost to cancer research in Europe," says Michael Baumann, Scientific Director and Chairman of the Board of DKFZ.
Michael Boutros, head of the project at DKFZ, is convinced that the focus of initiative on better networking of European research infrastructures and research data will significantly reduce existing hurdles in the fight against cancer. : an initiative to federate Member States against cancer
Across the 27 EU Member States, 2.7 million people are diagnosed with cancer every year and 1.3 million die from the disease, of which over 6,000 are children, adolescents and young adults. Over half a million of European citizens are childhood cancer survivors dealing with long-term effects of the disease and its treatment, with cancer being the leading cause of child mortality from disease in Europe. Cancer puts an immense pressure on health systems, which will only become stronger with increasing life expectancies.
A new level of investment to better understand cancer is needed to promote new thinking and hopefully new breakthroughs in our ability to prevent, diagnose and treat this disease. To this end, Europe calls for a strengthened collaboration among Member States to consolidate their stakes regarding data sciences to enable a leap forward in modern oncology and efficiently hinder the rise of disease burden.
The information, collected within, will be used by stakeholders in Europe and beyond to address the various urgent and critical scientific and medical challenges in cancer prevention, early diagnosis, treatment and survival, in men, women and children.
This initiative is expected to collect research and patient health data, as well other relevant data, at an unprecedented scale to gain new and deeper understanding of cancer mechanisms. The global ambition of this initiative is to further knowledge and guide improvements in cancer prevention, early diagnosis, and treatment, including treatment-related side effects. This will ultimately provide the basis to save millions of lives and improve the quality of life of cancer survivors and their caretakers.

Two main missions: building a Federated Data Hud and providing a Research Agenda
The blueprint for will integrate inequalities in cancer research across regions and Member States to boost the research potential of less-developed regions in Europe. A dedicated workpackage, led by the ECPC (, will ensure that patients' and citizens' expectations and priorities are heard and taken into account when identifying all challenges.
A Research Agenda including a series of use cases addressing urgent and essential scientific and medical needs in cancer prevention, early diagnosis, treatment and survivorship, in males and females of various ages will be delivered by the teams. This agenda will then be used to help determine the most competitive, ambitious and innovative cross-border and transdisciplinary research programs to invest in.
Players will be committed to open science principles, including FAIR (Findable, Accessible, Interoperable, and Reusable) guiding principles for scientific data collection, management and stewardship.
The new understanding gained from the collection and analysis of this wealth of data can be applied secondarily to other diseases.

A committed European team towards a stronger European research:
The meeting was opened by Prof. Eric Solary of Inserm, who coordinates the project. An introduction to the EU Cancer Mission and Horizon Europe – EU cancer funded research followed by Mrs Christine Chomienne, Mission Cancer Board and Mr Ioannis Vouldis, UNCAN Project Officer, respectively.
Dedicated presentations from Charles Swanton, CRUK (Evolution, Metastasis and Immune Evasion: Insights from TRACERx); Jan Korbel, EMBL (Cancer Research data Hub); and Genevieve Almouzni, Curie Institute (LifeTime initiative), followed.
The representatives of the 29 institutions and organizations participating in the project have highlighted the importance of this scientific initiative, renewing their commitment and support toward the project while the main point of the meeting was the presentation of the activities that the partners will carry out during the 15 months of this project.

More information about can be found at the project's website: 

With more than 3,000 employees, the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) is Germany’s largest biomedical research institute. DKFZ scientists identify cancer risk factors, investigate how cancer progresses and develop new cancer prevention strategies. They are also developing new methods to diagnose tumors more precisely and treat cancer patients more successfully. The DKFZ's Cancer Information Service (KID) provides patients, interested citizens and experts with individual answers to questions relating to cancer.

To transfer promising approaches from cancer research to the clinic and thus improve the prognosis of cancer patients, the DKFZ cooperates with excellent research institutions and university hospitals throughout Germany:

  • National Center for Tumor Diseases (NCT, 6 sites)
  • German Cancer Consortium (DKTK, 8 sites)
  • Hopp Children's Cancer Center (KiTZ) Heidelberg
  • Helmholtz Institute for Translational Oncology (HI-TRON Mainz) - A Helmholtz Institute of the DKFZ
  • DKFZ-Hector Cancer Institute at the University Medical Center Mannheim
  • National Cancer Prevention Center (jointly with German Cancer Aid)
The DKFZ is 90 percent financed by the Federal Ministry of Education and Research and 10 percent by the state of Baden-Württemberg. The DKFZ is a member of the Helmholtz Association of German Research Centers.


Subscribe to our RSS-Feed.

to top
powered by webEdition CMS